Search
Technetium Tc-99m sestamibi
go.drugbank.com/drugs/DB09161ApprovedInvestigationalTechnetium Tc-99m sestamibi (commonly sestamibi) is a pharmaceutical agent used in nuclear medicine imaging. … infarction (non-reversible defects); and 2) evaluating myocardial function and developing information for use in patient management decisions.
Categories: Compounds used in a research, industrial, or household setting, Diagnostic Uses of ChemicalsProducts: Kit for the Preparation of Technetium Tc99m SestamibiNedocromil
go.drugbank.com/drugs/DB00716ApprovedA pyranoquinolone derivative that inhibits activation of inflammatory cells which are associated with asthma, including eosinophils, neutrophils, macrophages, mast cells, monocytes, and platelets.
Synonyms: 9-Ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyrano(3,2-g)chinolin-2,8-dicarbonsäure, 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyrano(3,2-g)quinoline-2,8-dicarboxylic acidCategories: 4-Quinolones, Heterocyclic Compounds, 2-RingNalidixic acid
go.drugbank.com/drugs/DB00779ApprovedWithdrawnNalidixic acid is a synthetic 1,8-naphthyridine antimicrobial agent with a limited bacteriocidal spectrum. It is an inhibitor of the A subunit of bacterial DNA gyrase.
Synonyms: 1-Aethyl-7-methyl-1,8-naphthyridin-4-on-3-karbonsaeure, 3-carboxy-1-ethyl-7-methyl-1,8-naphthyridin-4-oneInternational brands: Huei YiIoxilan
go.drugbank.com/drugs/DB09135ApprovedWithdrawnIntravascular injection results in opacification of vessels in the path of flow of the contrast medium, permitting radiographic visualization of the internal structures of the human body until significant … Ioxilan is a tri-iodinated diagnostic contrast agent.
Synonyms: N-(2,3-dihydroxypropyl)-N’-(2- hydroxyethyl)-5-[N-(2,3-dihydroxypropyl) acetamido]-2,4,6-triiodoisophthal-amideCategories: Compounds used in a research, industrial, or household setting, Diagnostic Uses of ChemicalsRimegepant
go.drugbank.com/drugs/DB12457ApprovedInvestigationalsafer for use in patients with contraindications to standard therapy. … [L11028] It received FDA approval on February 27, 2020 for the acute treatment migraine headache,[L11974] and was subsequently approved by the European Commission in April 2022 for both the treatment and
Categories: MATE 1 Inhibitors, P-glycoprotein substratesAmiloride
go.drugbank.com/drugs/DB00594ApprovedInvestigationalThis inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. … Negative potential reduces secretion of potassium and hydrogen ions. Amiloride is used in conjunction with diuretics to spare potassium loss.
Synonyms: 3,5-diamino-N-carbamimidoyl-6-chloropyrazine-2-carboxamide, N-amidino-3,5-diamino-6-chloropyrazinecarboxamideMixtures: PLENACOR D, MODURETIC® TABLETASXanomeline
go.drugbank.com/drugs/DB15357ApprovedInvestigational[A264509] Advances in pre-clinical research and findings in clinical trials have led to a resurgence of interest in the cognition-enhancing potential of muscarinic agonists in schizophrenia, as it was … [L51713] It is approved as part of a combination product alongside [trospium], a muscarinic antagonist that acts primarily on peripheral muscarinic receptors in order to mitigate the risk and severity
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesAtrasentan
go.drugbank.com/drugs/DB06199ApprovedInvestigational[L52855] In April 2025, atrasentan was granted accelerated approval by the FDA for the reduction of proteinuria in patients with primary IgA nephropathy, becoming the first endothelin A receptor antagonist … Atrasentan is a novel, selective endothelin A receptor antagonist (SERA).
Categories: Cytochrome P-450 CYP2B6 Inducers, P-glycoprotein inhibitorsTriclabendazole
go.drugbank.com/drugs/DB12245ApprovedInvestigationalTriclabendazole was previously used in the treatment of fascioliasis in livestock, but is now approved for human use. … These parasites can infect humans following ingestion of larvae in contaminated water or food.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 SubstratesArimoclomol
go.drugbank.com/drugs/DB05025Approved[L51389] It is also being investigated in amyotrophic lateral sclerosis (ALS) [A264414, A264429] and inclusion body myositis.[A264419] … [L51384] Arimoclomol was approved by the FDA on September 20, 2024, making it the first treatment for Niemann-Pick disease, type C (NPC).
Synonyms: 3-PYRIDINECARBOXIMIDOYL CHLORIDE, N-((2R)-2-HYDROXY-3-(1-PIPERIDINYL)PROPOXY), 1-OXIDE, N-[(2R)-2-Hydroxy-3-(1-piperidyl)propoxy]pyridine-3-carboximidoyl chloride, 1-oxideCategories: MATE 1 Substrates, MATE 2 Substrates